CC Chemours Co
Chemicals & Allied Products · NYSE · SEC CIK 1627223 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.1%
TTM net income YoY56.0%
TTM EPS YoY56.2%
Revenue 3-yr CAGR-1.2%
Net income 3-yr CAGR—
Margins
Gross margin15.2%
Operating margin—
Net margin-2.6%
FCF margin3.6%
EBITDA margin—
Returns
ROE-71.8%
ROA-2.1%
ROIC (approx.)—
Asset turnover0.79x
Leverage & solvency
Liabilities / assets97.9%
Debt / equity24.73x
Current ratio1.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.60x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.54B | $1.59B | $1.38B | $1.33B | $1.50B | $1.61B | $1.37B | $1.36B |
| Cost of revenue | $1.31B | $1.30B | $1.17B | $1.17B | $1.26B | $1.34B | $1.13B | $1.09B |
| Gross profit | $231.00M | $286.00M | $212.00M | $156.00M | $233.00M | $278.00M | $236.00M | $265.00M |
| R&D expense | $24.00M | $27.00M | $26.00M | $27.00M | $26.00M | $28.00M | $27.00M | $26.00M |
| SG&A expense | — | $469.00M | $147.00M | $130.00M | $122.00M | $424.00M | $123.00M | $170.00M |
| Interest expense | $69.00M | $68.00M | $69.00M | $68.00M | $68.00M | $67.00M | $66.00M | $67.00M |
| Pretax income | $222.00M | -$1.00M | -$22.00M | -$67.00M | $38.00M | -$248.00M | $0 | $1.00M |
| Income tax | $26.00M | $273.00M | $7.00M | -$5.00M | -$8.00M | $131.00M | $5.00M | $12.00M |
| Net income | $196.00M | -$274.00M | -$29.00M | -$47.00M | $46.00M | -$380.00M | -$5.00M | -$11.00M |
| EPS (basic) | 1.29 | -1.81 | -0.19 | -0.31 | 0.31 | -2.53 | -0.03 | -0.08 |
| EPS (diluted) | 1.29 | -1.81 | -0.19 | -0.31 | 0.31 | -2.53 | -0.03 | -0.08 |
| Dividends declared per share | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.25 | 0.25 |
| Weighted avg. shares (diluted) | 151.91M | 151.23M | 150.77M | — | 150.78M | 150.24M | 149.92M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $698.00M | $671.00M | $563.00M | $670.00M | $665.00M | $553.00M | $514.00M | $763.00M |
| Receivables | $765.00M | $773.00M | $645.00M | $562.00M | $817.00M | $813.00M | $704.00M | $619.00M |
| Inventory | $1.48B | $1.45B | $1.54B | $1.57B | $1.55B | $1.56B | $1.55B | $1.46B |
| Current assets | $3.22B | $3.09B | $2.93B | $3.00B | $3.21B | $3.10B | $2.93B | $3.02B |
| PP&E, net | $3.00B | $3.03B | $3.04B | $3.08B | $3.10B | $3.13B | $3.14B | $3.19B |
| Goodwill | $46.00M | $46.00M | $46.00M | $46.00M | $46.00M | $46.00M | $46.00M | $46.00M |
| Intangibles | — | — | — | $2.00M | $2.00M | — | — | $3.00M |
| Total assets | $7.29B | $7.15B | $7.27B | $7.38B | $7.55B | $7.46B | $7.38B | $7.51B |
| Current liabilities | $1.78B | $1.86B | $1.61B | $1.69B | $1.87B | $1.83B | $1.67B | $1.82B |
| Short-term debt | $50.00M | $34.00M | $37.00M | $42.00M | $52.00M | $38.00M | $43.00M | $54.00M |
| Long-term debt | $3.78B | $3.84B | $4.10B | $4.10B | $4.10B | $4.11B | $4.07B | $4.06B |
| Total debt | $3.83B | $3.87B | $4.14B | $4.14B | $4.16B | $4.15B | $4.11B | $4.11B |
| Total liabilities | $7.14B | $7.20B | $7.05B | $7.13B | $7.27B | $7.23B | $6.81B | $6.94B |
| Shareholders' equity | $155.00M | -$49.00M | $215.00M | $250.00M | $274.00M | $228.00M | $566.00M | $571.00M |
| Net debt | $3.13B | $3.20B | $3.57B | $3.47B | $3.49B | $3.59B | $3.60B | $3.35B |
| Shares outstanding | 150.52M | 150.46M | 150.36M | 149.89M | 149.87M | 149.70M | 149.57M | 149.43M |
| Cash flow statement | ||||||||
| Operating cash flow | $149.00M | $158.00M | -$44.00M | $137.00M | $146.00M | $93.00M | -$112.00M | $138.00M |
| Capital expenditure | $51.00M | $44.00M | $49.00M | $45.00M | $41.00M | $43.00M | $84.00M | $109.00M |
| Free cash flow | $98.00M | $114.00M | -$93.00M | $92.00M | $105.00M | $50.00M | -$196.00M | $29.00M |
| Investing cash flow | -$7.00M | $239.00M | -$44.00M | -$43.00M | -$35.00M | -$42.00M | -$86.00M | -$107.00M |
| Financing cash flow | -$63.00M | -$289.00M | -$19.00M | -$37.00M | -$5.00M | -$27.00M | -$57.00M | $85.00M |
| Depreciation & amortization | $79.00M | $80.00M | $79.00M | $81.00M | $80.00M | $91.00M | $88.00M | $74.00M |
| Stock-based compensation | $4.00M | $7.00M | $7.00M | $4.00M | $5.00M | $7.00M | $5.00M | $3.00M |
| Dividends paid | $13.00M | $13.00M | $13.00M | $15.00M | $13.00M | $13.00M | $37.00M | $36.00M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.